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Abstract
There has been recent progress in the area of John-Cunningham virus (JCV) infection and progressive multifocal
leukoencephalopathy (PML). New drugs and better reporting identify new risk cohorts and importantly development
of new risk assessment strategies. The clinical presentation has not changed, but presentation of rarer forms of JCV
infection are now apparent. Brain magnetic resonance imaging (MRI) continues to be a pillar of PML diagnosis. The
imaging correlation with pathology and the new understanding of the biology and improved methods to detect JCV
significantly help with recent diagnostic criteria. Unfortunately a small number of trials for specific treatment of PML
have not proven beneficial, and the possibility remains to improve the JCV- specific immune response. Sometimes
this response creates an exacerbation of neurological features – immune reconstitution inflammatory syndrome –
that helps resolve the infection but can cause damage in itself. Overall, the prognosis of PML has improved with
much lower mortality but still severe neurological deficits.
This review aims to bring together old and new knowledge of PML and help reconsider practical clinical
strategies.
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Introduction
Our objective is to review the latest data on progressive multifocal
leukoencephalopathy (PML) ranging from clinical characteristics to
treatments and also relate the biological aspects of John-Cunningham
virus (JCV) to the understanding of the disease. In particular, we
propose to compare the features of PML in the context of human
immunodeficiency virus (HIV) positive individuals – HIV-PML- and
PML in the context of natalizumab treated multiple sclerosis (MS)
patients – Nat-PML to evolve learning points across areas of medicine
(Table 1).
It is striking that PML has become a misnomer: a) the progressive
nature of disease may be halted; b) unifocal rather than multifocal
lesions would not avert the diagnosis; c) the possibility of clinical and
imagiological features in grey matter only reflects the presence of
oligodendrocytes that has been highlighted, making it more than a
leukoencephalopathy.
Individuals at risk of PML
The individuals affected by PML are typically
immunocompromised people who have a deficient specific immune
response to JCV, either isolated or in a broader immunocompromised
context.
PML in people with very low CD4 count in the context of HIV
infection constituted the majority of presentations before the
combined anti-retroviral treatment (cART) era and it still is the cohort
where we derive a significant part our knowledge about JCV and PML.
In pre-cART days, PML occurred in 3%-7% of AIDS patients [1,2] and
was mostly terminal. Current treatments with cART from an earlier
stage of infection, with CD4 counts over 200 and reasonable viral load
suppression, have made PML significantly less frequent [3,4]. But late
presenters and people who do not adhere to medication have
increased risk of PML, often without having presented with the
opportunistic infections that characterise earlier stages of
immunosuppression.
PML in the context of immunosuppression with chemotherapeutic
regimens or oncologic disorders is recognised but not frequently
encountered. Possibly the recurrent nature of the regimens, rather
than long standing hits at the immune system, allows a better integrity
of the JCV immunity.
HIV-PML Nat-PML
Supratentorial clinical
presentation
93.8% 87.5%
Infratentorial clinical
presentation
58.3% 33.3%
Gadolinium-enhancing
lesions
15% 40%
Treatment cART; steroids could be
added
Natalizumab removal
(plasma exchange
and/or
immunoadsorption);
steroids could be
added
PML-IRIS risk cART naïve; cART initiation
close to opportunistic
infections treatment; higher
HIV viral load;
Virtually all patients
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rapid immune reconstitution
Survival Without cART: 5% or lower
With cART: 46-58%
71-100%
Good prognostic factor Higher CD4+ count; low HIV
RNA load; presence of JCV
specific cytotoxic T response;
low JCV viral load in the
CSF; inflammatory CSF
profile; PML as the heralding
manifestation of AIDS; older
age
Less pre-PML
neurological disability;
short time from
symptom onset to
diagnosis; more
localized lesions on
the MRI; younger age
Table 1: Summary of comparison between HIV-PML and Nat- PML.
HIV-PML -Progressive multifocal leucoencephalopathy in the context
of human immunodeficiency syndrome virus positive individuals;
Nat-PML-PML in the context of natalizumab treated multiple sclerosis
patients; IRIS-immune reconstitution inflammatory syndrome; cART-
combined anti-retroviral treatment; CSF-cerebrospinal fluid; AIDS-
acquired immune-deficiency syndrome; JCV-John Cunningham virus.
Since the introduction of natalizumab treatment – monthly
infusions of humanized monoclonal IgG antibodies against the cellular
adhesion molecule α4-integrine preventing lymphocytes to cross the
blood-brain barrier (BBB) and reducing inflammation within CNS -
for MS and Crohn’s disease, the occurrence of PML in this population
has highlighted a specific immunodeficiency to JCV infection. The risk
of PML in people who are treated with natalizumab increases with the
titre of JCV IgG, with the number of infusions and with previous
treatment with immunosuppressors, often mitoxantrone [5-7]. Risk
stratification algorithms model the probability that an individual has
to develop PML, but have not been shown to reduce its incidence [8].
There are exceptional cases where PML was detected in JCV sero-
negative individuals [9].
Patients with transplants, rheumatologic and other inflammatory
disorders (e.g. allogeneic hematopoietic cell transplantation, systemic
lupus erythematosus, inflammatory bowel disease, primary biliary
cirrhosis) are currently treated with diverse regimens that include
steroids, steroids sparing immunosuppressive drugs, specific
immunosuppressive treatments and biologicals antibodies [10] that
can cause immunosuppression but also compound the
immunodeficiency of diseases [11-15].
Specific immunodeficiencies such as low CD4 or CD8 counts are
found in individual cases who present with PML without known risk
factors. But conditions such as diabetes or pregnancy or old age can
induce immunosuppressive states [16]. A few individuals may present
with PML without any evidence for immunosuppression, the so called
healthy cases [17].
Clinical Presentation
Clinical presentations of PML are quite diverse and nonspecific.
The symptoms are dependent on the location and size of the lesions
and virtually any area of the brain can be involved [18,42]. It is usually
multisymptomatic, but can also present with only one prominent
objective neurologic abnormality at onset and remain monofocal
clinically and radiologically [42]. In fact, any clinical presentation is
possible for an individual affected with PML. Common clinical
findings include behavioural and cognitive abnormalities (seen in
25-30% of all patients), pyramidal signs, visual field defects (if the
occipital lobe or optic radiation are involved), aphasia (if there is
involvement of the dominant parietal lobe), cerebellar dysmetria or
ataxia and gait abnormalities. About 20% of patients with PML present
seizure activity associated with lesions immediately adjacent to the
hemispheric cortex [19]. Sensory loss, headache and diplopia are
reported less frequently [20,21]. It is usually a subacute process
(progressing over days to weeks) with an insidious, frequently
misdiagnosed, onset but with a fast accumulation of deficits [22].
It was commonly accepted that PML lesions spared the optic nerves
(and other cranial nerves), the spinal cord and the peripheral nervous
system. But a postmortem examination of an acquired
immunodeficiency syndrome (AIDS) patient revealed PML lesions in
the spinal cord and demonstrated that JCV can infect and affect any
part of the CNS [23].
Comparing the clinic presentation of HIV related PML (HIV-PML)
with natalizumab related PML (Nat-PML) it seems that infratentorial
manifestations are more frequent in HIV-PML. A study of 48 HIV-
PML patients showed that supratentorial manifestation of PML occur
in 93,8% and infratentorial manifestations in 58,3% of the patients.
The most affected infratentorial areas were the brainstem, mainly the
pons, followed by middle cerebellar peduncle and finally the cerebellar
white matter [24]. In a series of 15 patients with Nat-PML, at the onset
of the PML 12 patients had only supratentorial lesions, mostly in
frontal and parietal lobe, followed by occipital lobe and more rarely
temporal lobe. Only one patient presented with an infratentorial
(cerebellar) lesion and two patients had both supratentorial and
infratentorial lesions [25]. When this series was extended to include a
second hospital, 8/24 (33,3%) of patients had infratentorial
manifestations and of those, 3 were exclusively infratentorial and 5
were infratentorial and supratentorial [26]. The pons and cerebellum
were the most commonly affected infratentorial regions.
HIV-PML can present before cART even as the initial manifestation
of AIDS, early after initiation of cART (also known as unmasked
PML) and even later after cART (occurring more than 6 months after
cART initiation). There are no clinical or imaging differences between
the three situations [27]. In rare occasions, PML late after cART is
described in patients with high CD4+ T cell count and undetectable
HIV viremia, probably due to lack of specific JCV immunity [28].
When PML presents early after initiation of cART it possibly reflects
an immune reconstitution inflammatory syndrome (IRIS) with
unmasking of the lesion or, less likely, cART would initiate JCV
replication. But it is uncommon to detect brain magnetic resonance
imaging (MRI) characteristics of IRIS in patients with unmasked PML,
which suggests the presence of inflammation is below the imaging
threshold. Patients with unmasked PML tend to develop an adequate
immunological response to cART and have better prognosis [27].
In addition to this classic PML, some specific variants have been
described: JCV granular cell neuronopathy, JCV meningitis and JCV
encephalopathy [29,30].
Patients who have JCV granular cell neuronopathy present an
isolated progressive cerebellar syndrome and histopathologically only
cerebellar granule cell neurons are affected, with preservation of the
oligodendrocytes and astrocytes [31,32]. Wüthrich et al. [34] found
over two thirds of 43 PML patients (40 were HIV-positive) who had
hemispheric, but not cerebellar white matter lesions to have JCV
infection of the cerebellar granule cell layer (including glial cells and
cerebellar granule cell neurons). Granule cell neurons infection and
destruction may cause cerebellar dysfunction and atrophy, irrespective
of the presence of PML lesions in cerebellar white matter.
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JCV meningitis is described patients, both immune -deficient and -
competent individuals, who presented with meningitis in whom the
only etiological agent identified was JC virus [29].
JCV encephalopathy is considered with isolated progressive
cognitive deterioration and brain MRI lesions consistent with PML.
Neurological signs progress independently of initiation of cART with
viral suppression and CD4+ >200 and an increased number of larger
and enhancing lesions. Some cases have been shown to have a
preferential infection of the cortical pyramidal neurons and astrocytes
located in the cortical grey matter and grey-white junction and it was
found an extensive infection of the pyramidal cell neurons with
confirmation of JCV proteins in the nuclei, axons, and dendrites of
pyramidal cell. In white matter there was only a discreet infection of
the oligodendrocytes without the “typical” demyelination of PML [35].
Progression of the disease
PML remission is uncommon and might take several weeks, so no
strict criteria define clinical response. Currently, an assessment of
PML progression combines neurological features, brain MRI, and JCV
DNA measurement in cerebrospinal fluid [36]. This approach is useful
for showing disease stabilization or progression over a period of weeks
to months, but methods that help clinical decisions are yet to be
developed or validated. Because of the frequently rapid evolution of
the disease, clinical assessment every 2–4 weeks and MRI and
cerebrospinal fluid examination every 4–8 weeks seem reasonable
options. Additional MRI investigation can be recommended in case of
rapid clinical deterioration, particularly when inflammatory changes
associated with IRIS are suspected and to help exclude other diagnosis.
PML is considered inactive when there are no new or enlarging MRI
lesions, and the pattern of Gad enhancement is reduced. The
inflammatory PML appears in the setting of IRIS and will be
considered in that chapter [35].
Brain imaging and pathology
PML lesions may occur anywhere in the brain. Typically they are
single or multiple asymmetric white matter lesions that become
confluent and enlarge as disease progresses, without mass effect, in the
cortico-subcortical regions [37]. Brain MRI is significantly more
sensitive than CT [38] to identify PML lesions and it should be the
preferred imaging method. It is also the most sensitive tool to screen
suspected patients for PML, as it can detect early stage lesions, even
before they are clinically detectable [22]. In extremely rare cases the
patients can have clinically detectable neurologic deficits but no MRI
abnormalities due to the subcortical nature of the demyelination that
occur in PML, which may affect the cortex and not be easily visualized
on the currentl MRI scan sequences [38].
In MRI, PML shows lesions that are hyperintense on T2-weighted
and fluid-attenuated insertion recovery (FLAIR) images and
hypointense on T1-weighted images [39]. Nat-PML lesions are more
likely to have Gadolinium (Gad) enhancement then HIV-PML. At the
time of diagnosis, Gad enhancement may be present in as many as
15% of patients with HIV-PML [20]. and in 40% of Nat-PML [40].
Gad enhancement is usually sparse, with thin or reticulated
appearance adjacent on the edge of the lesions. These characteristics
may change with IRIS after cART.
Although it is considered a white matter disease, PML lesions are
mostly located in the the arcuate fibers (U fibers) between cortex and
white matter [22]. A revision of 40 Nat-PML patients detected cortical
involvement in 50% of early and in 71% of PML-IRIS patients. In this
series all lesions had a subcortical location, which was attributed to the
presence high blood flow [37,41]. The lesions are principally located in
supratentorial regions. The frontal lobes and parieto-occipital regions
are the regions that appear to be most commonly affected, presumably
as a consequence of their volume. However involvement of the basal
ganglia, external capsule and posterior fossa structures (cerebellum
and brainstem) are also seen [42]. The periventricular white matter is
usually spared [22]. Spinal cord lesions are possible but unusual and
raise the possibility of other alternative diagnosis. PML can also be
located primarily in the deep grey matter and display localizing signs
[43].
Advanced PML shows increased size and confluence of lesions,
further areas involved, varying degrees of cortical atrophy and
ventricular dilatation [22,44]. Metabolic characterisation by 1H-MR
spectroscopy shows that PML lesions have decreased N-acetylaspartate
(marker of neurons viability), increased lactate (correlated with
inflammation) and increased myoinositol. Increase in choline (a
constituent of cell membranes and indicative of cell membrane
breakdown) or increase in lipids (related to cell membrane breakdown,
or to infiltrating macrophages around inflammatory lesions) were
occasionally seen [45,46].
Many diseases can be mistaken for PML and need to be excluded,
particularly in patients with HIV, such as HIV encephalopathy,
cytomegalovirus infection, varicella-zoster leukoencephalitis, MS-like
illness, acute disseminated encephalomyelitis, CNS vasculitis,
reversible leukoencephalopathy associated with nucleoside analogue
antiretrovirals or white matter oedema associated with primary or
metastatic brain tumours [42] or even CD8 encephalitis [48].
Although cART alters the clinical course of the disease, it does not
seen to significantly influence the MRI PML patterns [44].
It is particularly difficult to distinguish PML and MS lesions in Nat-
PML. This is of extreme importance due to the risk of MS patients on
natalizumab to develop PML. While MS lesions tend to be
periventricular and small, Nat-PML lesions tend to be larger, confluent
and subcortical. The border of PML lesions tends to be sharp toward
the gray matter and ill-defined toward the white matter, and punctate
T2 hyperintensities may be seen in approximately 70% of the cases in
the vicinity of PML lesions [37,48].
Classic PML presents with focal neurologic deficits that gradually
worsen and histopathologically is characterized by multifocal areas of
demyelination, JCV-infected oligodendrocytes with intranuclear
inclusions (enlarged amphophilic nuclei) at the periphery of the
lesions, absent or mild inflammation, reactive gliosis with enlarged,
bizarre astrocytes, some of them sustaining JCV infection, and lipid-
laden macrophages [22,49] and the presence of JCV is confirmed by
immunohistochemistry, in situ nucleic acid hybridization, or electron
microscopy [50].
Infection with John-Cunningham virus (JCV), a human
polyomavirus
The prevalence of infection with various human polyomaviruses
(HPyVs), in particular JCV, is probably over 80%, but varies in
different populations and with detection method [44]. Typically the
primary infection is asymptomatic and occurs during childhood but
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can also happen at any stage in life. JCV infection evolves into a
chronic asymptomatic carrier state and the virus DNA can be detected
in urine (30%) and tonsils (40%) of healthy adults. In
immunocompromised people, JCV reactivates, becomes neurotropic
infects oligodendrocytes and causes PML [51]. Other HPyVs cause
trichodysplasiaspinulosa or Merkel cell carcinoma or polyomavirus
associated nephropathy. The specific factors that induce reactivation
and lytic infection seems associated with a defective host cellular
immune responses [52].
Recently, JCV has been shown to latently infect CD34+ bone
marrow cells that enter circulation and differentiate to CD19+ cells in
the peripheral blood and allow the growth of JCV [53].
The JC virus has two important genomic regions: the NCCR and
the VP1. The expressed VP1 binds the host cell surface receptors and
changes in its coding sequence are important in the pathogenesis of
PML [18]. The NCCR is a regulatory element that controls viral
transcription and replication. There are two forms of the virus that
differ in the NCCR region: the archetypal form that is typified by the
CY stain of the virus and is the form always found in kidney and urine;
and the prototypical form of the virus, also known as PML-type, that is
typified by the Mad-1 stain, the form always found in brain and the
one associated with PML. [54]. Whether the PML-type JCV originates
from a transmitted virus or arises from genetic rearrangements is
unknown. PML-type JCV is a more active viral variant because of the
deletion of negative control elements and/or the duplication of
positive control elements, and has the potential to cause lysis of glial
cell and PML [54]. Nevertheless, PML-type JCV is also found in the
peripheral blood cells in individuals without PML, indicating that
more factors are necessary for the pathogenicity of this virus [55].
Rarely, in the cerebellar syndrome that heralds the JCV granular cell
neuronopathy, unlike what is observed in the JCV infection in PML,
the majority of granule cell neurons expressed JCV T Ag (a protein
expressed early in the viral cycle) more frequently than JCV VP1 (that
is expressed late in the viral cycle,) which in conjunction with the fact
that one HIV-positive control patient, with no PML, had granule cell
neurons infection, led them suggest that granule cell neurons may be
the initial site of JC virus infection in the CNS.
The ability to detect the JCV depends on the sensitivity of the
quantitative polymerase chain reaction (PCR) techniques and on
cART. In the pre-cART era the detection of JCV in CSF by PCR had a
sensitivity of 90% with a specificity of 92-100%, but after the
introduction of cART the sensitivity dropped to 58%. In fact, IRIS with
CD4 above 100 cells/uL was an independent factor predict of the
failure to detect JCV in CSF of PML patients [56]. Nowadays, with
ultrasensitive PCR techniques, the sensitivity to detect JCV in CSF is
>95% [42]. Most diagnostic laboratories are able to detect >200 copies
of JC virus DNA/mL of CSF [42]. But despite the high sensitivity of the
PCR assays, a negative result does not exclude PML. In HIV-infected
patients, the viral load is usually high, but in HIV patients under
cART, in MS patients and other autoimmune diseases, the viral loads
are often lower and more likely to induce false negative results [42]. In
contrast, JCV can be detected in MS patients without PML [57]. CSF
analysis may be repeated if JCV PCR is negative but suspicion remains
high, and alternative diagnoses (e.g., focal VZV or primary CNS
lymphoma) were reasonably excluded by negative VZV PCR and IgG
and EBV PCR analysis respectively. Brain biopsy may be needed when
all else fails. In Nat-PML, as many as 70% have a JCV DNA level in
CSF under 100 copies/mL at the time of diagnosis [25,57].
A very sensitive two-step anti-JCV antibody assay (STRATIFY
JCV™; Focus Diagnostics, Cypress, CA, USA) [58] determines previous
JCV infection and helps stratify PML risk, if only in people who have
not taken immunosuppressors. JCV-specific cellular immune response
is highly prevalent in all JCV-seropositive MS patients, regardless of
treatment [59] but are more difficult to set up.
CSF JCV IgG index, rather than CSF JCV IgG to exclude pure
diffusion and disturbance of blood–CSF barrier, has been proposed to
help PML diagnosis. The argument is that in cases where the adaptive
immune response to JCV is maintained, the viral load is low but the
local production of JCV IgG is raised, but there are sensitivity
problems [57].
The diagnosis of PML remains rooted in a combination of
unspecific clinical presentation, reasonably distinct brain MR imaging,
plasma JCV IgG positivity and CSF JCV DNA in the appropriate risk
factor context.
Diagnostic criteria
In 2013 the AAN Neuroinfectious Disease Section, proposed new
diagnostic criteria for PML [42]. PML can be definitive or probable or
possible based on a combination of factors with or without
histopathological confirmation. In the cases when a brain biopsy or
post-mortem is available, definitive PML is based on histopathologic
features and requires the classic histopathologic triad of
demyelination, bizarre astrocytes and enlarged oligodendroglial nuclei,
associated with the presence of JC virus by electron microscopy,
immunohistochemistry or tissue PCR to have a definitive diagnosis.
Probable PML is defined if the classic histopathologic triad is present
but is not possible to demonstrate the presence of the JCV and is
possible if the virus is identified by electron microscopy or
immunohistochemistry but the classic histopathologic triad is not
present. Alternatively, the clinical features consistent with the
diagnosis associated with classic MRI findings and a positive CSF JCV
DNA is sufficient for a definitive diagnosis of PML. Probable PML is
determined if the clinical or the imaging features are not present but
CSF JCV DNA is present; and it is possible if both clinical or the
imaging features are present but CSF JCV DNA are not identified or if
both are absent but CSF JCV DNA is present. When clinical, MRI and
classic histopathologic features are present, and other diagnosis are
excluded, definitive diagnosis can be made even in the absence of JCV
identification by electron microscopy, immunohistochemistry or CSF
or tissue PCR.
In the reasonable clinical context, patients with probable PML
should be managed as definitive PML, while the management of
patients with possible PML remains a clinical decision.
Treatment
There are no specific anti-JCV infection treatments. The best
therapeutic option is to restore the immune system.
For people with HIV infection ART improves the prognosis of the
disease. The incidence of PML decreased after the introduction of
cART and it continued to decline over time probably associated with
its increase effectiveness [4]. The recommendations of the CDC, the
National Institutes of Health (NIH), and the HIV Medicine
Association of the Infectious Diseases Society of America (IDSA) [50]
depend on the patient's antiretroviral treatment status and its efficacy.
In patients who have PML and who are not on therapy, ART should be
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started immediately (AII). For patients with PML who remain HIV-
viremic because of antiretroviral resistance, their ART regimen should
be optimized for virologic suppression (AIII). Patients who have PML
despite successful virologic suppression while taking cART are more
problematic: ART-intensification strategy with four classes of ART is a
possibility, but its effectiveness requires further
studies (CIII). Approximately half of patients with PML in the setting
of HIV infection experience a remission after initiating effective ART.
When ART-induced immune reconstitution is associated with
either unmasking or paradoxical worsening of PML, corticosteroids
have also been used. However, no evidence supports the routine use of
corticosteroids in HIV-PML without an inflammatory response on
neuroimaging (DIII). In patients with inflammatory PML,
corticosteroid treatment might have a more rational basis [50]. Some
authors recommend corticosteroids in all cases of PML, even when
there is little evidence for inflammatory syndrome.
Especially when treatment fails to suppress HIV viral load, but also
when CD4+ count fails to recover, ART modification is needed.
Augmenting ART even when plasma HIV RNA is below detection is
controversial and under study. When PML progresses despite HIV
suppression, the informed use of unproven strategies is reasonable,
[50].
In HIV-negative patients potential sources of immunosuppression
should be removed or decreased as clinically possible [60] in order
sustain a JCV immune response.
In patients with Nat-PML treatment of PML depends on the
immune reconstitution after the removal of natalizumab. Plasma
exchange (PLEX) and immunoadsorption are used to hasten the
removal of natalizumab from circulation and allow JCV-specific
lymphocytes to cross the BBB. In a study of 15 patients with Nat-PML,
all patients received PLEX and / or immunoadsorption to re-establish
an immune response (5 only received PLEX, 1 only received
immunoadsorption and 9 patients received both treatments)
associated with a supportive therapy with mefloquine and mirtazapine
[25]. All patients showed initial improvement or stabilisation in the
weeks after PLEX and/or immunoadsorption, but 14 of the 15 patients
developed IRIS. There were no fatal cases recorded, with a median
follow-up time was 21.5 months from PML diagnosis. However, the
first 42 cases of Nat-PML cases since the reintroduction of
natalizumab showed that early IRIS in Nat-PML had worse survival
and neurologic outcome and that PLEX and/or immunoadsorption
may accelerate IRIS but the authors would not make a conclusion
about the strategy [40]. The use of corticosteroids is also advocated
when there is evidence of IRIS, which is more frequent in Nat-PML
than HIV-PML.
There are fewer options for HIV negative patients without
iatrogenic causes. The interaction between JCV and the serotonin 2A
receptor (5-HT2AR) is necessary for viral to entry the cell [61] so,
trials with drugs with 5HT2AR antagonism effect have been
attempted, such as risperidone [62] or mirtazapine [63].
Chlorpromazine [64] was also tried, due to its inhibition of clathrin-
dependent endocytosis required for virus infection. Drugs that inhibit
viral replication, such as cytarabine [65], cidofovir [66] or topotecan
[67], drugs that have immunomodulatory effect such as IL-2 [68-70],
IL-7 and interferons alfa e beta [71,72] and drugs, such as mefloquine,
which action mechanism is unknown [73] were also tried. However
none have proven any clinical benefit.
The research for specific anti-JCV infection causing PML continues
and is necessary to improve the outcomes of all individuals who
succumb to PML.
PML-IRIS
IRIS is clinically defined as the paradoxical worsening of disease
when the immune system is restored and the subsequent response to
antigens exacerbates the pathology. Systemically, it can affect many
organs systems, including central nervous system. In HIV-infected
patients, the initiation of ART decreases HIV-1 RNA level and
increases CD4+ cells from baseline; symptoms and signs must be
consistent with an inflammatory process to a recognised opportunistic
infection or tumour diagnosis and other diagnosis or drug toxicity are
excluded [74]. When treatment for the opportunistic infection is
initiated prior to cART, there will be a decreased microbial antigen
burdens and less risk of IRIS [74] In general, patients at highest risk
for IRIS are the ones who were ART naïve, or initiate CART closer to
the treatment of the opportunistic infections [74]. The higher initial
HIV viral load and the desired speed of immune reconstitution also
increase the risk of IRIS [74]. In the cases of PML, cART induces
restoration of a pathogen-specific immune response that leads to the
recognition of JCV antigens [29].
As previously mentioned, virtually all patients with Nat-PML
develop IRIS. This is probably because natalizumab does not alter the
JCV specific immune response, only prevents lymphocyte to cross the
BBB. So, when natalizumab is removed, the lymphocytes readily enter
the brain and develop an inflammatory reaction that both helps
eradicated the JCV infections and causes damage in itself [75]. IRIS
associated with PML can occur in two ways: “paradoxical” IRIS that
presents after the initiation of cART as an exacerbation of already
established PML; and “unmasking” IRIS when it reveals PML
pathology [76].
The pathophysiology of IRIS is not completely understood. In a
functioning immune system, T cells more than the humoral immune
response seem to control JCV reactivation and dissemination.
Compared to patients with PML, the ones that have PML-IRIS (either
HIV-PML or Nat-PML) have an inflammatory response that is
dominated by CD8+ T-cells directed against JCV and not to other
(self-) antigens [77]. This CD8+ T-cell response allows the control of
JCV dissemination, but also causes oligodendrocyte cell death and
demyelination. The influence of CD4+ T cell is less clear, but must be
important as HLA class II restricted immune responses are pivotal
for JCV infection control [78]. In HIV infected patients with PML-
IRIS CD4+ T-cells responses are not characteristic [77]. In Nat-PML,
the ratio of CD8+ T cell within the total of CD3+ T cell ranges from 24
to 70% [79].
There is no biomarker of IRIS. IRIS imaging shows limited CNS
inflammation and unlike typically PML where contrast enhancement
is usually absent, the PML-IRIS lesions are more likely to have Gad
enhancement suggestive of development of an inflammatory response
with breakdown of the BBB. However this only occurs in 56% of the
patients [79]. It had been shown that even when intense CD8+ T cell
infiltration is present Gad-enhancing lesions at the disease onset are
not consistently present [77]. So, a non-enhancing PML lesion with
clinical deterioration does not exclude the diagnosis of IRIS. By proton
magnetic resonance spectroscopy (1H-MRS), an increase in lipid/
creatine, coline/creatine and myo-inositol/creatine and a decrease in
NAA/creatine ratios in PML-IRIS lesions comparatively with patients
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with PML without IRIS is proposed [81]. Lipid / creatine ratios were
elevated in PML-IRIS lesions independently of contrast enhancement.
This way, 1H-MRS could become a tool to help in the diagnosis of
IRIS, but it has not been easy to use in clinical practice.
There is no consensus for PML-IRIS treatment. CDC, NIH, and the
HIV Medicine Association of IDSA recommend that corticosteroid
treatment should be as short as possible and not overused. Mild
swelling, oedema, or Gad enhancement might be noted in some
patients who respond favourably to ART, but most often these
complications require no additional treatment if the patient is
clinically stable and has no sign of impending brain herniation.
However, in those with progressing clinical deficits and neuroimaging
features suggesting inflammatory response (oedema, swelling, and
contrast enhancement), corticosteroid treatment is justified (BIII).
Although some have suggested stopping ART in the face of PML-IRIS,
this is likely counterproductive and is not recommended (DIII) [49].
In clinical practise, corticosteroids are used in high doses in PML-IRIS
patients who are progressing and have signs of inflammatory response,
associated with rapid weaning once there is clinical stabilization.
When the MRI signs of inflammation are vague, even if we know that
more than a third of patients will have inflammation, there is no
agreement and it usually depends on the severity of the clinical picture.
Prognosis
In HIV patients the main risk factor for the development of PML is
low CD4+ cell count, the risk of PML being low when the CD4+ cell
count is over 200 cells/uL [4]. During the pre-cART area, the median
survival time of PML patients was only a few months after the
diagnosis [82]. Since the introduction of cART, survival has improved
significantly, with a 1-year survival of about 46-58%, compared with
5% or lower in patients not receiving cART [83-85]. A study with 28
patients that tried a regimen of 5 ARV drugs after PML reached a 1-
year survival of 75% without increasing the risk of PML-associated
IRIS [86]. The factors that appear to be associated with better survival
include a higher CD4+ count, low HIV RNA load, presence of JCV
specific cytotoxic T lymphocytes, low JCV viral load in the CSF,
inflammatory CSF profile, PML as the heralding manifestation of
AIDS and older age [85].
In Nat-PML patients, in one study 71% of 35 PML patients were
alive at the time of the analysis and in another study 100% of 15
patients had survived [25,88]. Better prognostic factors were younger
age, lower pre-PML Expanded Disability Status Scale scores, a short
time from symptom onset to diagnosis and more localized lesions on
the MRI [88]. Despite the low numbers, Nat-PML has a better survival
compared with HIV-PML. However, PML patients who survive
frequently have irreversible severe neurological sequelae.
It was suggested that the CD4+ and CD8+ T cells against JC virus
have an important role in the clinical outcome of PML and PML-IRIS.
A study that tested the IFN-gamma production and the intracellular
cytokine staining to determine the activity of CD4+ and CD8+ T-cells
demonstrated that the cellular immune response against JCV is
associated with a better clinical outcome. PML survivors had an early
CD8+ T cell response more frequently than PML progressors (100%
versus 27,3%). For CD4+ T cells the difference between the two groups
was smaller (80% versus 45,5%). This suggests that these laboratorial
tests could be useful prognostic markers of PML evolution and may
help in the clinical management of these patients. Although IRIS was
more frequent in the PML survivor group, there was no difference in
IFNgamma production between IRIS and non-IRIS patients [89].
Patients who experience remission of PML after starting cART
seem to rarely suffer a subsequent recrudescence of PML, although no
formal study of this has been undertaken. The main preventive
measure is a good immunologic status [50].
Conclusion
PML has evolved from a deadly fate into a disease that is possible to
contain or even reverse, from multifocal to occasionally unifocal and
from white matter to whole brain disease sometimes with only gray
matter being affected. We reviewed some of the new findings in
context with old knowledge and put them into the context of new
cohorts of people at risk. The new cohorts have also informed us on
some aspects of JCV biology that may prove important to develop the
much-needed specific treatments for PML. In fact, even if the death
rate has improved consistently, the neurological outcomes of the
survivors need to be improved.
Current research in PML has been hindered by the small numbers
of cases that present in centres with active programmes and resources,
but more collaborative projects and better awareness of clinical trials
may develop knowledge and improve outcomes.
This review helps to highlight new and old information that is
important to address clinical practice and better diagnostic and
therapeutic strategies.
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